Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 63, n° 2
pages 252-258 (août 2010)
Doi : 10.1016/j.jaad.2009.09.018
accepted : 8 September 2009
Original Articles

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study
 

Hee Chul Eun, MD a, , Oh Sang Kwon, MD a, Je Ho Yeon, MD a, Hyo Seung Shin, MD a, Byung Yoon Kim, MD a, Byung In Ro, MD b, Han Kyong Cho, MD b, Woo Young Sim, MD c, Bark Lynn Lew, MD c, Won-Soo Lee, MD d, e, Hwa Young Park, MD d, Seung Phil Hong, MD d, Jae Hong Ji, MD d
a Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea 
b Department of Dermatology, Kwandong University College of Medicine, Koyang, Kyunggi, Korea 
c Department of Dermatology, College of Medicine, Kyong Hee University, Seoul, Korea 
d Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea 
e Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea 

Reprint requests: Hee Chul Eun, MD, Department of Dermatology, Seoul National University College of Medicine, Seoul National University Hospital, 101, Daehang-ro, Jongno-gu, Seoul, 110-744 Korea.
Abstract
Background

Dutasteride (Avodart) is a dual inhibitor of both type I and type II 5 alpha reductases, and thus inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss.

Objectives

The aim of this randomized double-blind phase III study was to compare the efficacy, safety, and tolerability of dutasteride (0.5 mg) and placebo for 6 months of treatment in male patients with male pattern hair loss.

Methods

A total of 153 men, 18 to 49 years old, were randomized to receive 0.5 mg of dutasteride or placebo daily for 6 months. Efficacy was evaluated by the change of hair counts, subject assessment, and photographic assessment by investigators and panels.

Results

Mean change of hair counts from baseline to 6 months after treatment start was an increase of 12.2/cm2 in dutasteride group and 4.7/cm2 in placebo group and this difference was statistically significant (P  = .0319). Dutasteride showed significantly higher efficacy than placebo group by subject self-assessment and by investigator and panel photographic assessment. There was no major difference in adverse events between two groups.

Limitations

The study was limited to 6 months.

Conclusions

This study clearly showed that 0.5 mg of dutasteride improved hair growth and was relatively well tolerated for the treatment of male pattern hair loss.

The full text of this article is available in PDF format.

Key words : androgenetic alopecia, dutasteride, male pattern hair loss, treatment

Abbreviations used : 5AR, DHT, HGI, MPHL



 Supported by GlaxoSmithKline.
 Conflicts of interest: None declared.



© 2009  American Academy of Dermatology, Inc.@@#104156@@